Market Research Logo

Scar - Pipeline Review, H2 2015

Scar - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Scar - Pipeline Review, H2 2015’, provides an overview of the Scar’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Scar, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Scar and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Scar
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Scar and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Scar products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Scar pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Scar
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Scar Overview
Therapeutics Development
Pipeline Products for Scar - Overview
Pipeline Products for Scar - Comparative Analysis
Scar - Therapeutics under Development by Companies
Scar - Therapeutics under Investigation by Universities/Institutes
Scar - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Scar - Products under Development by Companies
Scar - Products under Investigation by Universities/Institutes
Scar - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
AlbireoPharma
Altacor Limited
Beech Tree Labs, Inc.
Biokine Therapeutics Ltd.
Clanotech AB
Critical Outcome Technologies Inc.
Derma Sciences, Inc.
Easton Pharmaceuticals Inc.
EyeGene, Inc.
Fibrocell Science, Inc.
FirstString Research, Inc.
Isarna Therapeutics GmbH
Juventas Therapeutics, Inc.
LegoChem Biosciences, Inc
Moerae Matrix, Inc.
Pergamum AB
RXi Pharmaceuticals Corporation
Symic Biomedical, Inc.
VBS Pharmaceuticals
Scar - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3914 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-5425 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aclerastide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azficel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BKT-170 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLT-28643 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CM-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGS-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EP-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISTH-0036 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCB-030110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMI-0100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polysaccharide for Wounds and Scars - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXL-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Scar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-34240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Wounds and Scars - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate SOX-9 for Scar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tranilast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Scar - Recent Pipeline Updates
Scar - Dormant Projects
Scar - Discontinued Products
Scar - Product Development Milestones
Featured News & Press Releases
Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology
Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
Feb 03, 2014: RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the Specials Provision
Jul 15, 2013: FirstString Research, Inc. Announces the Achievement of Primary Endpoints in Three Phase 2 Clinical Trials of Granexin™ Gel for the Treatment of Chronic Wounds and Scar Reduction
Jul 12, 2013: RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Scar, H2 2015
Number of Products under Development for Scar - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Scar - Pipeline by 3M Drug Delivery Systems, H2 2015
Scar - Pipeline by AlbireoPharma, H2 2015
Scar - Pipeline by Altacor Limited, H2 2015
Scar - Pipeline by Beech Tree Labs, Inc., H2 2015
Scar - Pipeline by Biokine Therapeutics Ltd., H2 2015
Scar - Pipeline by Clanotech AB, H2 2015
Scar - Pipeline by Critical Outcome Technologies Inc., H2 2015
Scar - Pipeline by Derma Sciences, Inc., H2 2015
Scar - Pipeline by Easton Pharmaceuticals Inc., H2 2015
Scar - Pipeline by EyeGene, Inc., H2 2015
Scar - Pipeline by Fibrocell Science, Inc., H2 2015
Scar - Pipeline by FirstString Research, Inc., H2 2015
Scar - Pipeline by Isarna Therapeutics GmbH, H2 2015
Scar - Pipeline by Juventas Therapeutics, Inc., H2 2015
Scar - Pipeline by LegoChem Biosciences, Inc, H2 2015
Scar - Pipeline by Moerae Matrix, Inc., H2 2015
Scar - Pipeline by Pergamum AB, H2 2015
Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Scar - Pipeline by Symic Biomedical, Inc., H2 2015
Scar - Pipeline by VBS Pharmaceuticals, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Scar Therapeutics - Recent Pipeline Updates, H2 2015
Scar - Dormant Projects, H2 2015
Scar - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Scar, H2 2015
Number of Products under Development for Scar - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report